Literature DB >> 24067367

Genetic ablation of caveolin-2 sensitizes mice to bleomycin-induced injury.

Cecilia J G de Almeida1, Jean-François Jasmin, Francesco Del Galdo, Michael P Lisanti.   

Abstract

Caveolar domains act as platforms for the organization of molecular complexes involved in signal transduction. Caveolin proteins, the principal structural components of caveolae, have been involved in many cellular processes. Caveolin-1 (Cav-1) and caveolin-2 (Cav-2) are highly expressed in the lung. Cav-1-deficient mice (Cav-1(-/-)) and Cav-2-deficient mice (Cav-2(-/-)) exhibit severe lung dysfunction attributed to a lack of Cav-2 expression. Recently, Cav-1 has been shown to regulate lung fibrosis in different models. Here, we show that Cav-2 is also involved in modulation of the fibrotic response, but through distinct mechanisms. Treatment of wild-type mice with the pulmonary fibrosis-inducer bleomycin reduced the expression of Cav-2 and its phosphorylation at tyrosine 19. Importantly, Cav-2(-/-) mice, but not Cav-1(-/-) mice, were more sensitive to bleomycin-induced lung injury in comparison to wild-type mice. Bleomycin-induced lung injury was characterized by alveolar thickening, increase in cell density, and extracellular matrix deposition. The lung injury observed in bleomycin-treated Cav-2(-/-) mice was not associated with alterations in the TGF-β signaling pathway and/or in the ability to produce collagen. However, apoptosis and proliferation were more prominent in lungs of bleomycin-treated Cav-2(-/-) mice. Since Cav-1(-/-) mice also lack Cav-2 expression and show a different outcome after bleomycin treatment, we conclude that Cav-1 and Cav-2 have distinct roles in bleomycin induced-lung fibrosis, and that the balance of both proteins determines the development of the fibrotic process.

Entities:  

Keywords:  bleomycin; caveolae; caveolin; fibrosis; lung

Mesh:

Substances:

Year:  2013        PMID: 24067367      PMCID: PMC3755075          DOI: 10.4161/cc.25335

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  24 in total

1.  Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice.

Authors:  M Drab; P Verkade; M Elger; M Kasper; M Lohn; B Lauterbach; J Menne; C Lindschau; F Mende; F C Luft; A Schedl; H Haller; T V Kurzchalia
Journal:  Science       Date:  2001-08-09       Impact factor: 47.728

Review 2.  Apoptosis in lung fibrosis and repair.

Authors:  Bruce D Uhal
Journal:  Chest       Date:  2002-12       Impact factor: 9.410

3.  A new rat type I-like alveolar epithelial cell line R3/1: bleomycin effects on caveolin expression.

Authors:  Roland Koslowski; Kathrin Barth; Antje Augstein; Thomas Tschernig; Gerhard Bargsten; Michaela Aufderheide; Michael Kasper
Journal:  Histochem Cell Biol       Date:  2004-06-08       Impact factor: 4.304

Review 4.  Role of caveolae and caveolins in health and disease.

Authors:  Alex W Cohen; Robert Hnasko; William Schubert; Michael P Lisanti
Journal:  Physiol Rev       Date:  2004-10       Impact factor: 37.312

5.  Identification of a plasma membrane protein that specifically binds bleomycin.

Authors:  G Pron; J Belehradek; L M Mir
Journal:  Biochem Biophys Res Commun       Date:  1993-07-15       Impact factor: 3.575

6.  The scaffolding domain of caveolin 2 is responsible for its Golgi localization in Caco-2 cells.

Authors:  Lionel Breuza; Séverine Corby; Jean-Pierre Arsanto; Marie-Hélène Delgrossi; Peter Scheiffele; André Le Bivic
Journal:  J Cell Sci       Date:  2002-12-01       Impact factor: 5.285

7.  Caveolin-2-deficient mice show increased sensitivity to endotoxemia.

Authors:  Cecilia J de Almeida; Agnieszka K Witkiewicz; Jean-François Jasmin; Herbert B Tanowitz; Federica Sotgia; Philippe G Frank; Michael P Lisanti
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

8.  Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae.

Authors:  Babak Razani; Xiao Bo Wang; Jeffery A Engelman; Michela Battista; Guy Lagaud; Xiao Lan Zhang; Burkhard Kneitz; Harry Hou; George J Christ; Winfried Edelmann; Michael P Lisanti
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

Review 9.  Determination of hydroxyproline.

Authors:  H Stegemann; K Stalder
Journal:  Clin Chim Acta       Date:  1967-11       Impact factor: 3.786

10.  Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gp130-mediated cell signaling and proliferation.

Authors:  Yuben P Moodley; Amelia K Scaffidi; Neil L Misso; Carmel Keerthisingam; Robin J McAnulty; Geoff J Laurent; Steven E Mutsaers; Philip J Thompson; Darryl A Knight
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

View more
  5 in total

1.  Plasminogen activator inhibitor-1 suppresses profibrotic responses in fibroblasts from fibrotic lungs.

Authors:  Amarnath S Marudamuthu; Shwetha K Shetty; Yashodhar P Bhandary; Sophia Karandashova; Michael Thompson; Venkatachalem Sathish; Galina Florova; Taryn B Hogan; Christina M Pabelick; Y S Prakash; Yoshikazu Tsukasaki; Jian Fu; Mitsuo Ikebe; Steven Idell; Sreerama Shetty
Journal:  J Biol Chem       Date:  2015-02-03       Impact factor: 5.157

2.  Host deficiency in caveolin-2 inhibits lung carcinoma tumor growth by impairing tumor angiogenesis.

Authors:  Yajun Liu; Sungchan Jang; Leike Xie; Grzegorz Sowa
Journal:  Cancer Res       Date:  2014-09-30       Impact factor: 12.701

3.  Gene expression profiles analysis identifies key genes for acute lung injury in patients with sepsis.

Authors:  Zhiqiang Guo; Chuncheng Zhao; Zheng Wang
Journal:  Diagn Pathol       Date:  2014-09-26       Impact factor: 2.644

Review 4.  Caveolin-1 and Caveolin-2 Can Be Antagonistic Partners in Inflammation and Beyond.

Authors:  Cecília Jacques Gonçalves de Almeida
Journal:  Front Immunol       Date:  2017-11-17       Impact factor: 7.561

Review 5.  Potential contribution of alveolar epithelial type I cells to pulmonary fibrosis.

Authors:  Michael Kasper; Kathrin Barth
Journal:  Biosci Rep       Date:  2017-11-21       Impact factor: 3.840

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.